The next generation of drugs sees a number of market access challenges
A quiet revolution is underway in research to keep pace with changes in medical marketing
The best-selling book "The End of Illness" illustrates an exciting new way to think of healthcare—and healthcare marketing research
For the client-side market researcher, "doing more with less" is a mantra, if not a corporate way of life
For all the advances in technology and methodology, qualitative research cannot shed its history like its quant sibling
"External drivers" can have a significant impact on determining the answer to your marketing question
Marketing teams are not going to succeed in the future without a real understanding of the real world
A foundational premise of agency-of-record and preferred-provider relationships has a fatal flaw
As it became evident that a large HCV+ cohort would likely need medical intervention, pharma responded
In 2012, the phrase "pharmaceutical marketing research" seems a little wrong
Marketing continues to be a secondary consideration in the development process
Prescribing remains important, but it's half the picture: pharma's ultimate customer is the patient
These steps can equip sales teams to work around limited access, bring value to oncologists and increase sales
Most stakeholders have little or no knowledge of the Act's 1,500 pages of specifics or their implications
In a fast-changing industry, a constant is how the limited number of patients for trials hinders drug development
When it comes to multicultural marketing, a patient-centered focus is still an evolving, nascent notion in pharma
As we consider the role of social media in healthcare marketing, there is likely no other measure more important than "clout."
Social media can have a far-reaching impact on study time, costs, quality and outcomes
A survey shows that many leaders think "the current commercial pharmaceutical model is broken"
Some analysts predict that over half of all calls by 2015 will be fielded by NPs, PAs and others
Wrapping up what was remarkable about the past year, and pondering how the New Year will be the same and/or different.
Comparative Effectiveness Research (CER) is becomimg a key element in assessing the value of healthcare products.
How pharmaceutical marketing research could benefit from understanding behavioral economics.
A new kind of "soft" researcher may be in increasing demand: a "CreaSearcher," someone who combines creative and qualitative research, bridging what has traditionally been a gap between the two.
Over the last few months, I've been thinking a lot about trends in pharmaceutical marketing research.
The budgets and the personnel devoted to the generation of customer insight are shrinking, putting more pressure on market research functions to deliver value supportive of business priorities.
Understanding and measuring what motivates behavior is a central goal for many pharmaceutical market research projects.
I've had an epiphany! I have come to believe that much of pharma marketing research is conducted with the wrong respondents.
While industries like retail, hospitality and technology have endeavored to make customer experience a primary driver for innovation, the same cannot be said for most healthcare delivery systems.
The last two years saw controversy regarding the drug approval process.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Lawmakers propose allowing pharma companies to share some off-label information
- Apple's ResearchKit: Five Guidelines for Pharma
- Everyday Health buys rare-disease agency Cambridge BioMarketing